Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Children's Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Blood (2024) 144 (Supplement 1): 2808.1.

https://doi.org/10.1182/blood-2024-203724

Published: 2024

Journal Articles

A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Amanda M Li, Catherine Aftandilian, Susan Colace, Sarah Fanizzi, Kelly Elizabeth Faulk, Erin M. Guest, Ammar Hayani, Richard Ho, Anjali Khanna, Kasey Leger, David McCall, Tamara P. Miller, Holly Pacenta, Troy Quigg, Jeremy D. Rubinstein, Deepa Bhojwani, Susan R Rheingold, Maureen M. O'Brien, Karen R Rabin

Blood (2024) 144 (Supplement 1): 4204.

https://doi.org/10.1182/blood-2024-209455

Published: 2024

Journal Articles

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731

Blood (2024) 144 (Supplement 1): 1.

https://doi.org/10.1182/blood-2024-207450

Published: 2024

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2024) 144 (Supplement 1): 512.

https://doi.org/10.1182/blood-2024-205779

Published: 2024

Journal Articles

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

Blood (2024) 144 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2024-204115

Published: 2024

Journal Articles

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2023) 142 (Supplement 1): 1053.

https://doi.org/10.1182/blood-2023-190534

Published: 2023

Journal Articles

Inflammatory Markers in Hemophagocytic Lymphohistiocytosis - a Single Centre Study

Caroline Spaner, Mariam Goubran, Sophie Stukas, Kamran Shojania, Amanda M Li, Mypinder Sekhon, Cheryl Wellington, Adi Zoref-Lorenz, Andre Mattman, Erica A. Peterson, Michael B. Jordan, Luke Y. C. Chen, Audi Setiadi

Blood (2023) 142 (Supplement 1): 5359.

https://doi.org/10.1182/blood-2023-178867

Published: 2023

Journal Articles

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

Franco Locatelli, Peter Lang, Selim Corbacioglu, Donna Wall, Amanda M Li, Josu de La Fuente, Puja Kohli, Nanxin Li, Jaime Rubin, Siyu Zhang, Lanju Zhang, William Hobbs, Haydar Frangoul

Blood (2023) 142 (Supplement 1): 4997.

https://doi.org/10.1182/blood-2023-179916

Published: 2023

Journal Articles

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Colleen Annesley, Corinne Summers, Michael A. Pulsipher, Jodi L. Skiles, Amanda M. Li, Anant Vatsayan, Catherine Lindgren, Stephanie Mgebroff, Ashley Wilson, Wenjun Huang, Qian Vicky Wu, Josh Gustafson, Christopher Brown, Michael C. Jensen, Julie R. Park, Rebecca A Gardner

Blood (2021) 138 (Supplement 1): 470.

https://doi.org/10.1182/blood-2021-148881

Published: 2021

Journal Articles

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Amanda M. Li, Karen R Rabin, John Kairalla, Cindy Wang, Meenakshi Devidas, Olga Militano, Maki Okada, Johann K Hitzler, Anne L Angiolillo, Elizabeth A. Raetz, Mignon L. Loh, Sumit Gupta, Rachel E. Rau

Blood (2021) 138 (Supplement 1): 2304.

https://doi.org/10.1182/blood-2021-148967

Published: 2021

Journal Articles

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Amanda M. Li, MD, George E Hucks, Amanda M. Dinofia, MD, Alix E. Seif, MD, David T Teachey, MD, Diane Baniewicz, Colleen Callahan, Christina Fasano, Beth McBride, Vanessa Gonzalez, Farzana Nazimuddin, MS, David L. Porter, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephan A. Grupp, MD PhD, Shannon L. Maude, MD PhD

Blood (2018) 132 (Supplement 1): 556.

https://doi.org/10.1182/blood-2018-99-112572

Published: 2018

NARROW

A Children's Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Inflammatory Markers in Hemophagocytic Lymphohistiocytosis - a Single Centre Study

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only